APPENDIX IX
973
TABLE IX-1 (
co n tin u ed
)
Component
Present Reference
Interval
(Examples)
Present
Unit
Conversion
Factor
SI
Reference
Interval
SI Unit
Symbol
Significant
Digits
Suggested
Minimum
Increment
IgD
<6
mg/dL
10
<60
mg/L
xxo
10 mg/L
IgE
0-3 y
0.5-10
IU/mL
2.4
1-24
Mg/L
XX
1 Mg/L
3-80 y
5-100
IU/mL
2.4
12-240
Mg/L
XX
iMg/L
Imipramine (P)—therapeutic
50-200
ng/mL
3.566
180-710
nmol/L
xxo
10 nmol/L
Insulin (P, S)
5-20
jUU/mL
7.175
35-145
pmol/L
x x x
5 pmol/L
5-20
mU/L
7.175
35-145
pmol/L
XXX
5 pmol/L
0.20-0.84
jUg/mL
172.2
35-145
pmol/L
XXX
5 pmol/L
Iron (S)
male
80-180
jUg/dL
0.1791
14-32
Mmol/L
XX
1 Mmol/L
female
60-160
jUg/dL
0.1791
11-29
Mmol/L
XX
1 jijmol/L
Iron binding capacity (S)
250-460
jUg/dL
0.1791
45-82
Mmol/L
XX
1 Mmol/L
Isoniazid (P)—
therapeutic
<2.0
mg/L
7.291
<15
Mmol/L
XX
1 Mmol/L
toxic
<3.0
mg/L
7.291
>22
Mmol/L
XX
1 Mmol/L
Isopropanol (P)
0
mg/dL
0.1664
0
mmol/L
XX
1 mmol/L
Lactate (P) (as lactic acid)
0.5-2.0
mEq/L
1.00
0.5-2.0
mmol/L
x.x
0.1 mmol/L
5-20
mg/dL
0.1110
0.5-2.0
mmol/L
x.x
0.1 mmol/L
Lactate dehydrogenase (S)
50-150
U/L
0.01667
0.82-2.66
Mkat/L
x.x x
0.02 Mkat/L
Lactate dehydrogenase
isoenzymes (S)
LD1
15^10
%
0.01
0.15-0.40
1
o.xx
0.01
LD2
20-45
%
0.01
0.20-0.45
1
0.ХХ
0.01
LD3
15-30
%
0.01
0.15-0.30
1
0.ХХ
0.01
LD4
5-20
%
0.01
0.05-0.20
1
0.ХХ
0.01
LD5
5-20
%
0.01
0.05-0.20
1
0.ХХ
0.01
LD1
10-60
U/L
0.01667
0.16-1.00
Mkat/L
x.x x
0.02 Mkat/L
LD2
20-70
U/L
0.01667
0.32-1.16
Mkat/L
x.x x
0.02 Mkat/L
LD3
10-45
U/L
0.01667
0.22-0.76
Mkat/L
x.xx
0.02 Mkat/L
LD4
5-30
U/L
0.01667
0.08-0.50
Mkat/L
x.xx
0.02 Mkat/L
LD5
5-30
U/L
0.01667
0.02-0.50
Mkat/L
x.x x
0.02 Mkat/L
Lead (B)—toxic
>60
Mg/dL
0.04826
>2.90
Mmol/L
x.x x
0.05 Mmol/L
mg/dL
48.26
Mmol/L
x.x x
0.05 Mmol/L
Lead (U)—toxic
>80
Mg/24 h
0.004826
>0.40
Mmol/d
x.x x
0.05 jumol/d
Lidocaine (P) (Xylocaine)
1.0-5.0
mg/L
4.267
4.5-21.5
Mmol/L
x.x
0.5 Mmol/L
Lipase (S)
0-160
U/L
0.01667
0-2.66
Mkat/L
x.x x
0.02 Mkat/L
Lipids, total (P)
400-850
mg/dL
0.01
4.0-8.5
g/L
x.x x
0.1 g/L
Lipoproteins (P)
low-density (LDL)—
<100
mg/dL
0.02586
<2.60
mmol/L
x.x x
0.05 mmol/L
as cholesterol
high-density (HDL)—
as cholesterol
Optimal
40
mg/dL
0.02586
1.03
mmol/L
x.x x
0.05 mmol/L
Cardioprotective
>60
mg/dL
0.02586
1.55
mmol/L
x.x x
0.05 mmol/L
Lithium ion (S)—therapeutic
0.50-1.50
mEq/L
1.00
0.50-1.50
mmol/L
x.x x
0.05 mmol/L
Mg/dL
0.001441
mmol/L
x.x x
0.05 mmol/L
mg/dL
1.441
mmol/L
x.x x
0.05 mmol/L
Luteinizing hormone (S)
male
3-25
mlU/mL
1.00
3-25
IU/L
XXX
1 IU/L
female
2-20
mlU/mL
1.00
2-20
IU/L
XXX
1 IU/L
peak production
30-140
mlU/mL
1.00
30-140
IU/L
XXX
1 IU/L
Lysozyme (S) (muramidase)
1-15
Mg/mL
1.00
1-15
mg/L
XXX
1 mg/L
Lysozyme (U) (muramidase)
<2
Mg/mL
1.00
<2
mg/L
XX
1 mg/L
Magnesium (S)
1.8-3.0
mg/dL
0.4114
0.80-1.20
mmol/L
X.XX
0.02 mmol/L
1.6-2.4
mEq/L
0.5000
0.80-1.20
mmol/L
x.x x
0.02 mmol/L
Maprotiline (P)—therapeutic
50-200
ng/mL
3.605
180-720
nmo/L
xxo
10 nmol/L
Meprobamate (P)—
therapeutic
<20
mg/L
4.582
<90
дтоІ/L
xxo
10 Mmol/L
toxic
>40
mg/L
4.582
>180
Mmol/L
xxo
lOMmol/L
Mercury (B)—
normal
<1.0
Mg/dL
49.85
<50
nmol/L
xxo
10 nmol/L
chronic exposure
>20
Mg/dL
0.04985
>1.00
Mmol/L
x.x x
0.01 Mmol/L
